Provectus Biopharmaceuticals, Inc.
PVCT
$0.07
$0.006.82%
OTC PK
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 24.91% | -22.99% | |||
| Gross Profit | -24.91% | 22.99% | |||
| SG&A Expenses | 21.33% | -8.41% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 21.89% | -12.34% | |||
| Operating Income | -21.89% | 12.34% | |||
| Income Before Tax | -11.40% | 11.77% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -11.40% | 11.77% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 275.00% | -77.24% | |||
| Net Income | -10.77% | 11.16% | |||
| EBIT | -21.89% | 12.34% | |||
| EBITDA | -21.89% | 12.34% | |||
| EPS Basic | -10.71% | 9.68% | |||
| Normalized Basic EPS | -18.75% | 11.11% | |||
| EPS Diluted | -10.71% | 9.68% | |||
| Normalized Diluted EPS | -18.75% | 11.11% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||